Deleuran M, Marcoux D, De Bruin-Weller MS, Irvine AD, Baselga E, Ahn K, et al. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. Acta Derm Venereol [Internet]. 2021 Jul. 15 [cited 2024 Nov. 25];101(7):adv00504. Available from: https://medicaljournalssweden.se/actadv/article/view/133